INTRODUCTION {#s1}
============

The definition of gamma gap is the difference in total serum proteins and albumin, and a value above 3.5 or 4.0 g/dl is considered to be elevated. An elevated gamma gap was indicative of infections, malignancy, or other generalized inflammation. Previous literature has shown strong correlation between gamma gap and mortality, which may be due to gamma gap characterizing inflammatory status \[[@R1]\]. Among those with high levels of gamma gap, having adequate cardiorespiratory fitness is of importance in reducing mortality \[[@R2]\]. Of additional interest to the present study is a less investigated factor related to mortality among people with an elevated gamma gap, the mid-arm muscle circumference (MAMC). The MAMC is calculated as: mid-upper arm circumference (MAC) (cm) − 0.3142 x triceps skinfold (TS) thickness (mm), which is a single most portable and simple measurement. It is salient to establish the contributions of the widely applicable, convenient, and inexpensive anthropometric indices as well as potential mechanisms linking anthropometric indices to mortality to inform the development of specific prevention and intervention strategies in people with elevated gamma gaps. The aim of this investigation is to explore the potential protective effects of the MAMC on mortality in people with elevated gamma gaps. The National Health and Nutrition Examination Survey (NHANES) III database was adopted in this study. We assessed the associations of MAMC and all-cause mortality, cancer mortality, and cardiovascular (CV) mortality among people with and without elevated gamma gaps, respectively.

RESULTS {#s2}
=======

Preliminary analysis {#s2_1}
--------------------

The study included 14,011 adults with 6,688 (47.7%) male and 7,323 (52.3%) female participants. The mean MAMC was 25.9 ± 3.9 cm and the mean age was 47.8 ± 19.1 years. In our analytical cohort study, 3,432 deaths occurred during a mean follow-up of 14.3 years, including 1,898 male and 1,534 female.

Study sample characteristics {#s2_2}
----------------------------

Table [1](#T1){ref-type="table"} presented the demographic and clinical characteristics of the study population by MAMC tertiles. Of the participants, higher levels of body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), serum total cholesterol (TC), serum total triglycerides (TG), serum glucose, serum low-density lipoprotein (LDL), serum uric acid (UA), aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum total bilirubin, and serum albumin were observed in higher MAMC tertiles. However, higher gamma gap, serum high-density lipoprotein (HDL), and C-reactive protein (CRP) levels were shown in the lower MAMC tertiles. Male participants increased as female participants decreased in the higher MAMC tertiles. Asthma and smoking tended to increase in the higher MAMC tertiles while other cancer had an opposite trend. Higher percentages of non-Hispanic white, type 2 diabetes mellitus (DM), stroke, and congestive heart failure (CHF) were presented in the higher MAMC tertiles. Nonetheless, the maximal percentage of skin cancer was in the second tertile of MAMC.

###### Characteristics of the study participants by mid-arm muscle circumference tertiles

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics of the study participants    Tertiles of mid-arm muscle circumference (cm)   Total\              *P* for trend                           
                                                                                               *n* = 14,011                                                
  -------------------------------------------- ----------------------------------------------- ------------------- ------------------- ------------------- ----------
  **Continuous variables**^**a**^                                                                                                                          

  MAMC (cm), mean (SE)                         21.673 (1.410)                                  25.739 (1.161)      30.373 (2.081)      25.929 (3.897)      \< 0.001

  Gamma Gap (g/dL), mean (SE)                  3.259 (0.477)                                   3.258 (0.481)       3.223 (0.482)       3.247 (0.480)       \< 0.001

  Age (years), mean (SE)                       46.130 (19.994)                                 50.840 (19.972)     46.360 (16.829)     47.780 (19.112)     \< 0.001

  BMI (kg/m^2^), mean (SE)                     24.010 (4.012)                                  27.130 (4.889)      29.290 (5.254)      26.810 (5.218)      \< 0.001

  SBP (mmHg), mean (SE)                        120.170 (23.101)                                127.830 (22.694)    128.020 (18.885)    125.340 (21.947)    \< 0.001

  DBP (mmHg), mean (SE)                        68.110 (13.085)                                 72.280 (12.836)     76.780 (12.030)     72.390 (13.144)     \< 0.001

  Serum TG (mg/dL), mean (SE)                  122.090 (96.320)                                144.880 (106.942)   166.730 (137.438)   144.580 (116.335)   \< 0.001

  Serum total cholesterol (mg/dL), mean (SE)   203.190 (45.959)                                207.310 (45.771)    207.320 (42.813)    205.940 (44.909)    \< 0.001

  Serum HDL-cholesterol (mg/dL), mean (SE)     56.860 (15.856)                                 50.770 (15.387)     45.960 (13.731)     51.200 (15.667)     \< 0.001

  Serum LDL-cholesterol (mg/dL), mean (SE)     122.130 (38.758)                                129.190 (38.832)    132.060 (37.862)    127.810 (38.707)    \< 0.001

  Serum glucose (mg/dL), mean (SE)             94.500 (33.250)                                 102.180 (38.038)    102.820 (38.649)    100.17 (36.947)     \< 0.001

  Serum CRP (mg/dL), mean (SE)                 0.452 (0.836)                                   0.500 (0.781)       0.437 (0.663)       0.463 (0.764)       \< 0.001

  Serum UA (mg/dL), mean (SE)                  4.509 (1.258)                                   5.422 (1.389)       6.122 (1.372)       5.451 (1.495)       \< 0.001

  AST (U/L), mean (SE)                         20.080 (12.203)                                 22.520 (18.028)     24.730 (16.610)     22.440 (15.922)     \< 0.001

  ALT (U/L), mean (SE)                         14.280 (13.059)                                 17.320 (15.723)     22.490 (20.143)     18.030 (16.910)     \< 0.001

  Serum total bilirubin (umol/L), mean (SE)    0.529 (0.301)                                   0.590 (0.319)       0.667 (0.365)       0.595 (0.334)       \< 0.001

  Serum albumin (g/dL), mean (SE)              4.081 (0.372)                                   4.135 (0.383)       4.216 (0.358)       4.144 (0.375)       \< 0.001

  **Categorical variables**^**b**^                                                                                                                         

  Gender (male), *N* (%)                       272 (5.8)                                       2314 (49.6)         4102 (87.8)         6688 (47.7)         \< 0.001

  Non-Hispanic white, *N* (%)                  1195 (25.6)                                     1320 (28.3)         1300 (27.8)         3815 (27.2)         \< 0.001

  Type 2 diabetes mellitus, *N* (%)            250 (5.4)                                       429 (9.2)           409 (8.8)           1088 (7.8)          \< 0.001

  Malignancy, *N* (%)                          203 (4.3)                                       201 (4.3)           117 (2.5)           521 (3.7)           \< 0.001

  Stroke, *N* (%)                              97 (2.1)                                        156 (3.3)           100 (2.1)           353 (2.5)           \< 0.001

  Congestive heart failure, *N* (%)            107 (2.3)                                       207 (4.4)           167 (3.6)           481 (3.4)           \< 0.001

  Asthma, *N* (%)                              300 (6.4)                                       323 (6.9)           345 (7.4)           968 (6.9)           0.251

  Smoking, *N* (%)                             76 (1.6)                                        520 (11.1)          983 (21.0)          1579 (11.3)         \< 0.001
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations:

N, number; SE, standard errors; MAMC, mid-arm muscle circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; Serum TG, serum total triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Serum CRP, serum C-reactive protein; Serum UA, serum uric acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

^a^Values were expressed as mean (standard errors).

^b^Values in the categorical variables were expressed as number (%).

The cut-off point of the gamma gap {#s2_3}
----------------------------------

To further investigated the relationship between the MAMC and all-cause mortality, cancer mortality, and CV mortality, we divided the participants into 2 groups based on the gamma gap level. The P value of the interaction test between MAMC and gamma gap was \< 0.001. The receiver operating characteristic (ROC) curves of gamma gap for detecting all-cause mortality, cancer mortality, and CV mortality was performed. ROC curve was used for predicting the ethnic-specific cut-off points of gamma gap and the area under curve (AUC) was calculated with 95% confidence interval (CI). The optimal AUC (95% CI) was 0.534 (0.523 -- 0.545) for all-cause mortality, 0.533 (0.512 -- 0.555) for cancer mortality, and 0.528 (0.512 -- 0.544) for CV mortality when gamma gap was 3.65 g/dl. The three mortality outcomes had identical cut-off value of gamma gap; therefore, we divided the participants into groups with gamma gap \< 3.65 g/dl and ≥ 3.65 g/dl.

Association between the MAMC and all-cause mortality, cancer mortality, and cardiovascular mortality {#s2_4}
----------------------------------------------------------------------------------------------------

Cox proportional hazards models stratified by age, BMI, and gender were utilized to determine the hazard ratios (HRs) for all-cause mortality, cancer mortality, and CV mortality associated with the MAMC in the 2 gamma gap groups. Multivariable adjusted analyses were conducted and the results were shown in Tables [2](#T2){ref-type="table"}--[10](#T10){ref-type="table"}.

###### Cox proportional hazards regression of all-cause mortality for mid-arm muscle circumference stratified by age in the US individuals

  ----------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)   GammaGap ≥ 3.65 (g/dL)                                                                                
  ------------------------- ------------------------ -------------------- ---------- --------- ------------- -------------------- --------
  **Aged 20--39 years**     **Aged 20--39 years**                                                                                 

  Model 1                   T2 v.s. T1\              1.77 (1.12--2.81)\   0.015\     Model 1   T2 v.s. T1\   1.69 (0.88--3.23)\   0.112\
                            T3 v.s. T1               2.66 (1.75--4.04)    \< 0.001             T3 v.s. T1    1.81 (0.94--3.48)    0.076

  Model 2                   T2 v.s. T1\              1.32 (0.75--2.33)\   0.330\     Model 2   T2 v.s. T1\   1.31 (0.65--2.65)\   0.457\
                            T3 v.s. T1               1.58 (0.83--3.00)    0.159                T3 v.s. T1    0.94 (0.38--2.33)    0.891

  Model 3                   T2 v.s. T1\              1.34 (0.76--2.37)\   0.309\     Model 3   T2 v.s. T1\   1.48 (0.71--3.09)\   0.299\
                            T3 v.s. T1               1.66 (0.87--3.19)    0.126                T3 v.s. T1    0.98 (0.39--2.47)    0.960

  Model 4                   T2 v.s. T1\              1.34 (0.76--2.37)\   0.312\     Model 4   T2 v.s. T1\   1.43 (0.68--3.01)\   0.341\
                            T3 v.s. T1               1.65 (0.86--3.17)    0.132                T3 v.s. T1    0.97 (0.38--2.48)    0.950

  **Aged 40--59 years**     **Aged 40--59 years**                                                                                 

  Model 1                   T2 v.s. T1\              1.64 (1.24--2.16)\   \<0.001\   Model 1   T2 v.s. T1\   1.59 (1.02--2.49)\   0.040\
                            T3 v.s. T1               1.36 (1.04--1.78)    0.026                T3 v.s. T1    1.44 (0.91--2.26)    0.117

  Model 2                   T2 v.s. T1\              1.20 (0.88--1.65)\   0.253\     Model 2   T2 v.s. T1\   1.15 (0.71--1.85)\   0.567\
                            T3 v.s. T1               0.88 (0.60--1.27)    0.481                T3 v.s. T1    0.69 (0.40--1.20)    0.186

  Model 3                   T2 v.s. T1\              1.21 (0.88--1.66)\   0.233\     Model 3   T2 v.s. T1\   1.18 (0.72--1.92)\   0.510\
                            T3 v.s. T1               0.88 (0.61--1.28)    0.513                T3 v.s. T1    0.77 (0.43--1.36)    0.370

  Model 4                   T2 v.s. T1\              1.21 (0.88--1.66)\   0.240\     Model 4   T2 v.s. T1\   1.14 (0.70--1.87)\   0.596\
                            T3 v.s. T1               0.88 (0.60--1.28)    0.492                T3 v.s. T1    0.77 (0.43--1.38)    0.382

  **Aged 60--90 years**     **Aged 60--90 years**                                                                                 

  Model 1                   T2 v.s. T1\              1.17 (1.06--1.30)\   0.002\     Model 1   T2 v.s. T1\   0.89 (0.73--1.07)\   0.220\
                            T3 v.s. T1               0.88 (0.78--0.99)    0.034                T3 v.s. T1    0.89 (0.72--1.09)    0.268

  Model 2                   T2 v.s. T1\              1.02 (0.91--1.15)\   0.744\     Model 2   T2 v.s. T1\   0.74 (0.60--0.90)\   0.004\
                            T3 v.s. T1               0.91 (0.79--1.06)    0.223                T3 v.s. T1    0.71 (0.56--0.91)    0.008

  Model 3                   T2 v.s. T1\              1.01 (0.9--1.14)\    0.839\     Model 3   T2 v.s. T1\   0.74 (0.60--0.91)\   0.005\
                            T3 v.s. T1               0.9 (0.78--1.05)     0.186                T3 v.s. T1    0.67 (0.52--0.86)    0.002

  Model 4                   T2 v.s. T1\              1.01 (0.9--1.14)\    0.864\     Model 4   T2 v.s. T1\   0.75 (0.61--0.93)\   0.007\
                            T3 v.s. T1               0.90 (0.78--1.05)    0.170                T3 v.s. T1    0.69 (0.54--0.89)    0.004
  ----------------------------------------------------------------------------------------------------------------------------------------

^a^Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + gender, race and body mass index (BMI).

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol, serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

###### Cox proportional hazards regression of all-cause mortality for mid-arm muscle circumference stratified by body mass index (BMI) in the US individuals

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)              GammaGap ≥ 3.65 (g/dL)                                                                                             
  ------------------------------------ ------------------------------------ -------------------- ----------- --------- ------------- -------------------- -----------
  **BMI 19--24.9 (kg/m**^**2**^**)**   **BMI 19--24.9 (kg/m**^**2**^**)**                                                                                 

  Model 1                              T2 v.s. T1\                          1.51 (1.33--1.73)\   \< 0.001\   Model 1   T2 v.s. T1\   1.58 (1.23--2.01)\   \< 0.001\
                                       T3 v.s. T1                           0.64 (0.52--0.79)    \< 0.001              T3 v.s. T1    0.71 (0.48--1.06)    0.094

  Model 2                              T2 v.s. T1\                          0.87 (0.73--1.04)\   0.134\      Model 2   T2 v.s. T1\   0.70 (0.51--0.96)\   0.026\
                                       T3 v.s. T1                           0.80 (0.61--1.05)    0.108                 T3 v.s. T1    0.52 (0.32--0.84)    0.007

  Model 3                              T2 v.s. T1\                          0.89 (0.74--1.07)\   0.202\      Model 3   T2 v.s. T1\   0.67 (0.49--0.92)\   0.014\
                                       T3 v.s. T1                           0.83 (0.63--1.08)    0.173                 T3 v.s. T1    0.51 (0.31--0.81)    0.005

  Model 4                              T2 v.s. T1\                          0.90 (0.75--1.08)\   0.250\      Model 4   T2 v.s. T1\   0.66 (0.47--0.91)\   0.012\
                                       T3 v.s. T1                           0.84 (0.64--1.09)    0.189                 T3 v.s. T1    0.52 (0.32--0.84)    0.008

  **BMI 25--29.9 (kg/m**^**2**^**)**   **BMI 25--29.9 (kg/m**^**2**^**)**                                                                                 

  Model 1                              T2 v.s. T1\                          1.97 (1.67--2.33)\   \< 0.001\   Model 1   T2 v.s. T1\   2.08 (1.52--2.83)\   \< 0.001\
                                       T3 v.s. T1                           0.95 (0.80--1.13)    0.564                 T3 v.s. T1    1.82 (1.31--2.52)    \< 0.001

  Model 2                              T2 v.s. T1\                          1.09 (0.90--1.31)\   0.382\      Model 2   T2 v.s. T1\   1.06 (0.75--1.50)\   0.725\
                                       T3 v.s. T1                           0.83 (0.66--1.06)    0.138                 T3 v.s. T1    0.98 (0.64--1.52)    0.943

  Model 3                              T2 v.s. T1\                          1.08 (0.90--1.31)\   0.401\      Model 3   T2 v.s. T1\   1.04 (0.74--1.48)\   0.811\
                                       T3 v.s. T1                           0.83 (0.65--1.05)    0.127                 T3 v.s. T1    0.89 (0.57--1.37)    0.595

  Model 4                              T2 v.s. T1\                          1.07 (0.89--1.30)\   0.464\      Model 4   T2 v.s. T1\   1.06 (0.74--1.50)\   0.753\
                                       T3 v.s. T1                           0.82 (0.64--1.04)    0.105                 T3 v.s. T1    0.86 (0.55--1.33)    0.495

  **BMI ≥ 30 (kg/m**^**2**^**)**       **BMI ≥ 30 (kg/m**^**2**^**)**                                                                                     

  Model 1                              T2 v.s. T1\                          1.39 (1.00--1.93)\   0.049\      Model 1   T2 v.s. T1\   1.57 (0.94--2.61)\   0.082\
                                       T3 v.s. T1                           1.63 (1.19--2.24)    0.002                 T3 v.s. T1    2.19 (1.34--3.59)    0.002

  Model 2                              T2 v.s. T1\                          1.23 (0.89--1.72)\   0.214\      Model 2   T2 v.s. T1\   0.99 (0.60--1.66)\   0.983\
                                       T3 v.s. T1                           1.34 (0.94--1.91)    0.110                 T3 v.s. T1    1.17 (0.69--2.00)    0.558

  Model 3                              T2 v.s. T1\                          1.24 (0.89--1.73)\   0.197\      Model 3   T2 v.s. T1\   0.97 (0.58--1.63)\   0.921\
                                       T3 v.s. T1                           1.34 (0.94--1.92)    0.104                 T3 v.s. T1    1.11 (0.65--1.90)    0.693

  Model 4                              T2 v.s. T1\                          1.25 (0.90--1.74)\   0.185\      Model 4   T2 v.s. T1\   0.99 (0.59--1.66)\   0.973\
                                       T3 v.s. T1                           1.37 (0.96--1.96)    0.084                 T3 v.s. T1    1.20 (0.70--2.05)    0.503
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + age, gender, and race.

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol, serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

###### Cox proportional hazards regression of all-cause mortality for mid-arm muscle circumference stratified by gender in the US individuals

  --------------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)   GammaGap ≥ 3.65 (g/dL)                                                                                 
  ------------------------- ------------------------ -------------------- ----------- --------- ------------- -------------------- -----------
  Male                      Male                                                                                                   

  Model 1                   T2 v.s. T1\              0.49 (0.40--0.60)\   \< 0.001\   Model 1   T2 v.s. T1\   0.47 (0.34--0.64)\   \< 0.001\
                            T3 v.s. T1               0.24 (0.20--0.30)    \< 0.001              T3 v.s. T1    0.22 (0.16--0.30)    \< 0.001

  Model 2                   T2 v.s. T1\              0.76 (0.62--0.94)\   0.010\      Model 2   T2 v.s. T1\   0.67 (0.49--0.92)\   0.012\
                            T3 v.s. T1               0.59 (0.48--0.73)    \< 0.001              T3 v.s. T1    0.49 (0.35--0.68)    \< 0.001

  Model 3                   T2 v.s. T1\              0.78 (0.63--0.95)\   0.014\      Model 3   T2 v.s. T1\   0.65 (0.47--0.89)\   0.007\
                            T3 v.s. T1               0.61 (0.49--0.75)    \< 0.001              T3 v.s. T1    0.46 (0.33--0.64)    \< 0.001

  Model 4                   T2 v.s. T1\              0.78 (0.63--0.95)\   0.015\      Model 4   T2 v.s. T1\   0.60 (0.44--0.83)\   0.002\
                            T3 v.s. T1               0.61 (0.49--0.75)    \< 0.001              T3 v.s. T1    0.44 (0.31--0.61)    \< 0.001

  Female                    Female                                                                                                 

  Model 1                   T2 v.s. T1\              1.39 (1.22--1.57)\   \< 0.001\   Model 1   T2 v.s. T1\   1.06 (0.85--1.33)\   0.602\
                            T3 v.s. T1               1.62 (1.31--2.00)    \< 0.001              T3 v.s. T1    1.58 (1.18--2.11)    0.002

  Model 2                   T2 v.s. T1\              1.06 (0.94--1.21)\   0.334\      Model 2   T2 v.s. T1\   0.83 (0.66--1.03)\   0.096\
                            T3 v.s. T1               1.46 (1.18--1.81)    0.001                 T3 v.s. T1    1.23 (0.92--1.65)    0.156

  Model 3                   T2 v.s. T1\              1.05 (0.93--1.19)\   0.435\      Model 3   T2 v.s. T1\   0.80 (0.64--1.01)\   0.062\
                            T3 v.s. T1               1.43 (1.15--1.77)    0.001                 T3 v.s. T1    1.21 (0.90--1.62)    0.208

  Model 4                   T2 v.s. T1\              1.05 (0.92--1.19)\   0.049\      Model 4   T2 v.s. T1\   0.82 (0.65--1.03)\   0.091\
                            T3 v.s. T1               1.41 (1.14--1.75)    0.002                 T3 v.s. T1    1.26 (0.93--1.69)    0.131
  --------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + age, race and body mass index (BMI).

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol , serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

###### Cox proportional hazards regression of cancer mortality for mid-arm muscle circumference stratified by age in the US individuals

  --------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)   GammaGap ≥ 3.65 (g/dL)                                                                              
  ------------------------- ------------------------ -------------------- -------- --------- ------------- -------------------- --------
  **Aged 20--39 years**     **Aged 20--39 years**                                                                               

  Model 1                   T2 v.s. T1\              0.86 (0.39--1.92)\   0.721\   Model 1   T2 v.s. T1\   1.45 (0.36--5.81)\   0.598\
                            T3 v.s. T1               0.60 (0.25--1.41)    0.241              T3 v.s. T1    1.31 (0.29--5.86)    0.726

  Model 2                   T2 v.s. T1\              1.16 (0.49--2.74)\   0.740\   Model 2   T2 v.s. T1\   1.27 (0.30--5.40)\   0.746\
                            T3 v.s. T1               1.11 (0.31--3.95)    0.869              T3 v.s. T1    1.06 (0.14--7.88)    0.954

  Model 3                   T2 v.s. T1\              1.28 (0.53--3.10)\   0.587\   Model 3   T2 v.s. T1\   1.27 (0.29--5.48)\   0.752\
                            T3 v.s. T1               1.39 (0.38--5.12)    0.622              T3 v.s. T1    1.09 (0.15--8.09)    0.935

  Model 4                   T2 v.s. T1\              1.28 (0.53--3.10)\   0.586\   Model 4   T2 v.s. T1\   1.37 (0.32--5.94)\   0.673\
                            T3 v.s. T1               1.39 (0.38--5.14)    0.621              T3 v.s. T1    1.14 (0.16--8.16)    0.897

  **Aged 40--59 years**     **Aged 40--59 years**                                                                               

  Model 1                   T2 v.s. T1\              1.52 (1.02--2.28)\   0.040\   Model 1   T2 v.s. T1\   1.08 (0.47--2.45)\   0.863\
                            T3 v.s. T1               1.04 (0.69--1.55)    0.863              T3 v.s. T1    0.90 (0.38--2.12)    0.812

  Model 2                   T2 v.s. T1\              1.14 (0.72--1.80)\   0.569\   Model 2   T2 v.s. T1\   0.86 (0.35--2.11)\   0.742\
                            T3 v.s. T1               0.72 (0.41--1.25)    0.240              T3 v.s. T1    0.53 (0.18--1.58)    0.255

  Model 3                   T2 v.s. T1\              1.16 (0.74--1.84)\   0.519\   Model 3   T2 v.s. T1\   0.98 (0.39--2.47)\   0.960\
                            T3 v.s. T1               0.75 (0.43--1.32)    0.320              T3 v.s. T1    0.67 (0.22--2.00)    0.468

  Model 4                   T2 v.s. T1\              1.17 (0.74--1.85)\   0.495\   Model 4   T2 v.s. T1\   1.08 (0.42--2.79)\   0.873\
                            T3 v.s. T1               0.76 (0.44--1.34)    0.346              T3 v.s. T1    0.67 (0.22--2.05)    0.482

  **Aged 60--90 years**     **Aged 60--90 years**                                                                               

  Model 1                   T2 v.s. T1\              1.54 (1.20--1.96)\   0.001\   Model 1   T2 v.s. T1\   1.09 (0.73--1.64)\   0.678\
                            T3 v.s. T1               1.34 (1.03--1.73)    0.028              T3 v.s. T1    1.17 (0.76--1.78)    0.472

  Model 2                   T2 v.s. T1\              1.11 (0.85--1.46)\   0.448\   Model 2   T2 v.s. T1\   0.60 (0.38--0.95)\   0.028\
                            T3 v.s. T1               0.90 (0.65--1.25)    0.521              T3 v.s. T1    0.49 (0.29--0.83)    0.008

  Model 3                   T2 v.s. T1\              1.11 (0.84--1.46)\   0.457\   Model 3   T2 v.s. T1\   0.66 (0.42--1.04)\   0.073\
                            T3 v.s. T1               0.90 (0.64--1.25)    0.517              T3 v.s. T1    0.53 (0.31--0.88)    0.015

  Model 4                   T2 v.s. T1\              1.11 (0.84--1.47)\   0.446\   Model 4   T2 v.s. T1\   0.66 (0.42--1.04)\   0.076\
                            T3 v.s. T1               0.87 (0.62--1.21)    0.404              T3 v.s. T1    0.57 (0.33--0.96)    0.036
  --------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + gender, race and body mass index (BMI).

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol , serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

###### Cox proportional hazards regression of cancer mortality for mid-arm muscle circumference stratified by body mass index (BMI) in the US individuals

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)              GammaGap ≥ 3.65 (g/dL)                                                                                             
  ------------------------------------ ------------------------------------ -------------------- ----------- --------- ------------- -------------------- --------
  **BMI 19--24.9 (kg/m**^**2**^**)**   **BMI 19--24.9 (kg/m**^**2**^**)**                                                                                 

  Model 1                              T2 v.s. T1\                          1.67 (1.27--2.20)\   \< 0.001\   Model 1   T2 v.s. T1\   2.06 (1.24--3.42)\   0.005\
                                       T3 v.s. T1                           0.91 (0.61--1.34)    0.630                 T3 v.s. T1    1.09 (0.53--2.21)    0.816

  Model 2                              T2 v.s. T1\                          0.95 (0.63--1.43)\   0.815\      Model 2   T2 v.s. T1\   0.30 (0.15--0.63)\   0.001\
                                       T3 v.s. T1                           0.94 (0.55--1.61)    0.825                 T3 v.s. T1    0.27 (0.11--0.69)    0.006

  Model 3                              T2 v.s. T1\                          0.99 (0.66--1.48)\   0.961\      Model 3   T2 v.s. T1\   0.29 (0.13--0.61)\   0.001\
                                       T3 v.s. T1                           1.01 (0.59--1.72)    0.985                 T3 v.s. T1    0.26 (0.10--0.66)    0.005

  Model 4                              T2 v.s. T1\                          1.00 (0.66--1.51)\   0.995\      Model 4   T2 v.s. T1\   0.29 (0.13--0.63)\   0.002\
                                       T3 v.s. T1                           0.99 (0.58--1.70)    0.973                 T3 v.s. T1    0.24 (0.09--0.63)    0.004

  **BMI 25--29.9 (kg/m**^**2**^**)**   **BMI 25--29.9 (kg/m**^**2**^**)**                                                                                 

  Model 1                              T2 v.s. T1\                          2.45 (1.72--3.51)\   \< 0.001\   Model 1   T2 v.s. T1\   2.14 (1.17--3.92)\   0.013\
                                       T3 v.s. T1                           1.23 (0.85--1.77)    0.278                 T3 v.s. T1    2.21 (1.20--4.07)    0.011

  Model 2                              T2 v.s. T1\                          1.20 (0.80--1.79)\   0.372\      Model 2   T2 v.s. T1\   0.74 (0.36--1.51)\   0.406\
                                       T3 v.s. T1                           0.69 (0.42--1.13)    0.138                 T3 v.s. T1    0.66 (0.28--1.57)    0.352

  Model 3                              T2 v.s. T1\                          1.24 (0.83--1.84)\   0.289\      Model 3   T2 v.s. T1\   0.77 (0.39--1.53)\   0.458\
                                       T3 v.s. T1                           0.73 (0.45--1.19)    0.210                 T3 v.s. T1    0.64 (0.28--1.48)    0.300

  Model 4                              T2 v.s. T1\                          1.22 (0.82--1.82)\   0.330\      Model 4   T2 v.s. T1\   0.77 (0.39--1.55)\   0.467\
                                       T3 v.s. T1                           0.69 (0.42--1.13)    0.140                 T3 v.s. T1    0.66 (0.28--1.52)    0.327

  **BMI ≥ 30 (kg/m**^**2**^**)**       **BMI ≥ 30 (kg/m**^**2**^**)**                                                                                     

  Model 1                              T2 v.s. T1\                          1.65 (0.80--3.38)\   0.172\      Model 1   T2 v.s. T1\   2.46 (0.73--8.24)\   0.145\
                                       T3 v.s. T1                           2.10 (1.05--4.18)    0.035                 T3 v.s. T1    3.04 (0.92--10.04)   0.068

  Model 2                              T2 v.s. T1\                          1.52 (0.74--3.12)\   0.258\      Model 2   T2 v.s. T1\   1.32 (0.39--4.48)\   0.654\
                                       T3 v.s. T1                           1.59 (0.73--3.48)    0.246                 T3 v.s. T1    1.38 (0.39--4.96)    0.618

  Model 3                              T2 v.s. T1\                          1.50 (0.73--3.09)\   0.272\      Model 3   T2 v.s. T1\   1.36 (0.40--4.65)\   0.624\
                                       T3 v.s. T1                           1.48 (0.68--3.23)    0.324                 T3 v.s. T1    1.33 (0.37--4.78)    0.659

  Model 4                              T2 v.s. T1\                          1.51 (0.73--3.12)\   0.261\      Model 4   T2 v.s. T1\   1.21 (0.35--4.21)\   0.766\
                                       T3 v.s. T1                           1.46 (0.67--3.19)    0.345                 T3 v.s. T1    1.33 (0.37--4.77)    0.666
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + age, gender, and race.

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol , serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

###### Cox proportional hazards regression of cancer mortality for mid-arm muscle circumference stratified by gender in the US individuals

  ------------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)   GammaGap ≥ 3.65 (g/dL)                                                                                
  ------------------------- ------------------------ -------------------- ---------- --------- ------------- -------------------- ----------
  **Male**                  **Male**                                                                                              

  Model 1                   T2 v.s. T1\              0.59 (0.37--0.96)\   0.032\     Model 1   T2 v.s. T1\   0.39 (0.21--0.73)\   0.003\
                            T3 v.s. T1               0.33 (0.21--0.53)    \< 0.001             T3 v.s. T1    0.15 (0.08--0.29)    \< 0.001

  Model 2                   T2 v.s. T1\              0.94 (0.58--1.51)\   0.793\     Model 2   T2 v.s. T1\   0.37 (0.20--0.70)\   0.002\
                            T3 v.s. T1               0.69 (0.43--1.12)    0.130                T3 v.s. T1    0.26 (0.13--0.50)    \< 0.001

  Model 3                   T2 v.s. T1\              1.03 (0.64--1.67)\   0.903\     Model 3   T2 v.s. T1\   0.46 (0.23--0.92)\   0.027\
                            T3 v.s. T1               0.78 (0.48--1.26)    0.309                T3 v.s. T1    0.32 (0.15--0.65)    0.002

  Model 4                   T2 v.s. T1\              1.01 (0.62--1.63)\   0.975\     Model 4   T2 v.s. T1\   0.44 (0.22--0.88)\   0.021\
                            T3 v.s. T1               0.74 (0.46--1.21)    0.233                T3 v.s. T1    0.32 (0.15--0.67)    0.002

  **Female**                **Female**                                                                                            

  Model 1                   T2 v.s. T1\              1.57 (1.22--2.04)\   0.001\     Model 1   T2 v.s. T1\   1.02 (0.62--1.66)\   0.952\
                            T3 v.s. T1               1.41 (0.86--2.31)    0.169                T3 v.s. T1    1.76 (0.96--3.25)    0.069

  Model 2                   T2 v.s. T1\              1.14 (0.88--1.48)\   0.320\     Model 2   T2 v.s. T1\   0.74 (0.45--1.22)\   0.236\
                            T3 v.s. T1               1.14 (0.70--1.87)    0.597                T3 v.s. T1    1.32 (0.72--2.43)    0.376

  Model 3                   T2 v.s. T1\              1.13 (0.87--1.46)\   0.375\     Model 3   T2 v.s. T1\   0.74 (0.45--1.22)\   0.239\
                            T3 v.s. T1               1.08 (0.66--1.78)    0.757                T3 v.s. T1    1.37 (0.74--2.54)    0.320

  Model 4                   T2 v.s. T1\              1.13 (0.87--1.47)\   0.345\     Model 4   T2 v.s. T1\   0.73 (0.44--1.22)\   0.231\
                            T3 v.s. T1               1.08 (0.65--1.77)    0.773                T3 v.s. T1    1.42 (0.76--2.64)    0.273
  ------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + age, race and body mass index (BMI).

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol , serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

###### Cox proportional hazards regression of cardiovascular mortality for mid-arm muscle circumference stratified by age in the US individuals

  ---------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)   GammaGap ≥ 3.65 (g/dL)                                                                               
  ------------------------- ------------------------ --------------------- -------- --------- ------------- -------------------- --------
  **Aged 20--39 years**     **Aged 20--39 years**                                                                                

  Model 1                   T2 v.s. T1\              5.75 (1.24--26.60)\   0.025\   Model 1   T2 v.s. T1\   0.97 (0.16--5.83)\   0.977\
                            T3 v.s. T1               10.56 (2.46--45.33)   0.002              T3 v.s. T1    3.22 (0.81--12.89)   0.098

  Model 2                   T2 v.s. T1\              7.22 (1.48--35.31)\   0.015\   Model 2   T2 v.s. T1\   0.37 (0.04--3.49)\   0.388\
                            T3 v.s. T1               16.46 (3--90.26.00)   0.001              T3 v.s. T1    0.52 (0.04--6.08)    0.600

  Model 3                   T2 v.s. T1\              6.92 (1.4--34.17)\    0.018\   Model 3   T2 v.s. T1\   0.44 (0.04--4.31)\   0.481\
                            T3 v.s. T1               14.39 (2.55--81.08)   0.003              T3 v.s. T1    0.54 (0.04--6.66)    0.634

  Model 4                   T2 v.s. T1\              6.98 (1.41--34.42)\   0.017\   Model 4   T2 v.s. T1\   0.39 (0.04--3.87)\   0.420\
                            T3 v.s. T1               14.08 (2.49--79.55)   0.003              T3 v.s. T1    0.39 (0.03--5.83)    0.495

  **Aged 40--59 years**     **Aged 40--59 years**                                                                                

  Model 1                   T2 v.s. T1\              2.19 (1.28--3.72)\    0.004\   Model 1   T2 v.s. T1\   1.73 (0.78--3.83)\   0.175\
                            T3 v.s. T1               2.28 (1.38--3.78)     0.001              T3 v.s. T1    2.00 (0.93--4.33)    0.077

  Model 2                   T2 v.s. T1\              1.46 (0.80--2.67)\    0.214\   Model 2   T2 v.s. T1\   1.39 (0.60--3.21)\   0.445\
                            T3 v.s. T1               1.27 (0.64--2.50)     0.494              T3 v.s. T1    1.13 (0.44--2.91)    0.805

  Model 3                   T2 v.s. T1\              1.47 (0.81--2.69)\    0.209\   Model 3   T2 v.s. T1\   1.32 (0.56--3.07)\   0.525\
                            T3 v.s. T1               1.28 (0.64--2.53)     0.484              T3 v.s. T1    1.13 (0.43--2.97)    0.807

  Model 4                   T2 v.s. T1\              1.41 (0.77--2.58)\    0.268\   Model 4   T2 v.s. T1\   1.13 (0.48--2.69)\   0.774\
                            T3 v.s. T1               1.19 (0.60--2.37)     0.613              T3 v.s. T1    1.05 (0.39--2.84)    0.927

  **Aged 60--90 years**     **Aged 60--90 years**                                                                                

  Model 1                   T2 v.s. T1\              1.20 (1.03--1.38)\    0.016\   Model 1   T2 v.s. T1\   0.81 (0.61--1.07)\   0.136\
                            T3 v.s. T1               0.85 (0.72--1.00)     0.054              T3 v.s. T1    0.76 (0.56--1.04)    0.089

  Model 2                   T2 v.s. T1\              1.07 (0.91--1.25)\    0.443\   Model 2   T2 v.s. T1\   0.68 (0.50--0.92)\   0.012\
                            T3 v.s. T1               0.99 (0.80--1.22)     0.913              T3 v.s. T1    0.65 (0.44--0.94)    0.022

  Model 3                   T2 v.s. T1\              1.05 (0.89--1.24)\    0.547\   Model 3   T2 v.s. T1\   0.68 (0.50--0.92)\   0.013\
                            T3 v.s. T1               0.97 (0.78--1.20)     0.770              T3 v.s. T1    0.62 (0.42--0.91)    0.013

  Model 4                   T2 v.s. T1\              1.06 (0.90--1.25)\    0.486\   Model 4   T2 v.s. T1\   0.67 (0.49--0.91)\   0.011\
                            T3 v.s. T1               0.97 (0.78--1.20)     0.750              T3 v.s. T1    0.62 (0.42--0.91)    0.014
  ---------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + gender, race and body mass index (BMI).

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol , serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

###### Cox proportional hazards regression of cardiovascular mortality for mid-arm muscle circumference stratified by body mass index (BMI) in the US individuals

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)              GammaGap ≥ 3.65 (g/dL)                                                                                             
  ------------------------------------ ------------------------------------ -------------------- ----------- --------- ------------- -------------------- --------
  **BMI 19--24.9 (kg/m**^**2**^**)**   **BMI 19--24.9 (kg/m**^**2**^**)**                                                                                 

  Model 1                              T2 v.s. T1\                          1.62 (1.33--1.97)\   \< 0.001\   Model 1   T2 v.s. T1\   1.46 (0.99--2.16)\   0.056\
                                       T3 v.s. T1                           0.48 (0.34--0.70)    \< 0.001              T3 v.s. T1    0.39 (0.18--0.86)    0.019

  Model 2                              T2 v.s. T1\                          1.08 (0.84--1.39)\   0.539\      Model 2   T2 v.s. T1\   0.53 (0.32--0.90)\   0.018\
                                       T3 v.s. T1                           0.98 (0.64--1.50)    0.913                 T3 v.s. T1    0.45 (0.18--1.15)    0.094

  Model 3                              T2 v.s. T1\                          1.09 (0.85--1.41)\   0.481\      Model 3   T2 v.s. T1\   0.49 (0.28--0.84)\   0.010\
                                       T3 v.s. T1                           1.00 (0.65--1.54)    0.993                 T3 v.s. T1    0.42 (0.16--1.07)    0.069

  Model 4                              T2 v.s. T1\                          1.12 (0.87--1.44)\   0.373\      Model 4   T2 v.s. T1\   0.45 (0.25--0.80)\   0.006\
                                       T3 v.s. T1                           1.01 (0.65--1.56)    0.964                 T3 v.s. T1    0.40 (0.15--1.05)    0.061

  **BMI 25--29.9 (kg/m**^**2**^**)**   **BMI 25--29.9 (kg/m**^**2**^**)**                                                                                 

  Model 1                              T2 v.s. T1\                          2.02 (1.58--2.57)\   \< 0.001\   Model 1   T2 v.s. T1\   1.92 (1.20--3.08)\   0.007\
                                       T3 v.s. T1                           0.88 (0.68--1.15)    0.348                 T3 v.s. T1    1.45 (0.87--2.43)    0.153

  Model 2                              T2 v.s. T1\                          0.94 (0.71--1.24)\   0.674\      Model 2   T2 v.s. T1\   0.98 (0.58--1.64)\   0.930\
                                       T3 v.s. T1                           0.78 (0.55--1.11)    0.172                 T3 v.s. T1    0.65 (0.32--1.30)    0.224

  Model 3                              T2 v.s. T1\                          0.94 (0.71--1.25)\   0.680\      Model 3   T2 v.s. T1\   0.96 (0.57--1.61)\   0.864\
                                       T3 v.s. T1                           0.78 (0.54--1.11)    0.165                 T3 v.s. T1    0.63 (0.31--1.27)    0.200

  Model 4                              T2 v.s. T1\                          0.92 (0.69--1.21)\   0.543\      Model 4   T2 v.s. T1\   0.93 (0.55--1.59)\   0.793\
                                       T3 v.s. T1                           0.75 (0.52--1.07)    0.117                 T3 v.s. T1    0.60 (0.29--1.22)    0.156

  **BMI ≥ 30 (kg/m**^**2**^**)**       **BMI ≥ 30 (kg/m**^**2**^**)**                                                                                     

  Model 1                              T2 v.s. T1\                          1.42 (0.89--2.26)\   0.142\      Model 1   T2 v.s. T1\   1.47 (0.71--3.03)\   0.302\
                                       T3 v.s. T1                           1.63 (1.04--2.54)    0.033                 T3 v.s. T1    2.20 (1.09--4.43)    0.028

  Model 2                              T2 v.s. T1\                          1.22 (0.76--1.95)\   0.404\      Model 2   T2 v.s. T1\   0.81 (0.39--1.68)\   0.571\
                                       T3 v.s. T1                           1.33 (0.79--2.22)    0.279                 T3 v.s. T1    1.07 (0.50--2.27)    0.862

  Model 3                              T2 v.s. T1\                          1.23 (0.77--1.98)\   0.379\      Model 3   T2 v.s. T1\   0.89 (0.43--1.86)\   0.761\
                                       T3 v.s. T1                           1.35 (0.81--2.25)    0.251                 T3 v.s. T1    1.10 (0.52--2.34)    0.800

  Model 4                              T2 v.s. T1\                          1.22 (0.76--1.95)\   0.416\      Model 4   T2 v.s. T1\   0.95 (0.45--2.00)\   0.895\
                                       T3 v.s. T1                           1.38 (0.83--2.31)    0.213                 T3 v.s. T1    1.34 (0.62--2.88)    0.454
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + age, gender, and race.

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol , serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

###### Cox proportional hazards regression of cardiovascular mortality for mid-arm muscle circumference stratified by gender in the US individuals

  --------------------------------------------------------------------------------------------------------------------------------------------
  GammaGap \< 3.65 (g/dL)   GammaGap ≥ 3.65 (g/dL)                                                                                 
  ------------------------- ------------------------ -------------------- ----------- --------- ------------- -------------------- -----------
  **Male**                  **Male**                                                                                               

  Model 1                   T2 v.s. T1\              0.46 (0.34--0.61)\   \< 0.001\   Model 1   T2 v.s. T1\   0.40 (0.24--0.67)\   \< 0.001\
                            T3 v.s. T1               0.20 (0.15--0.27)    \< 0.001              T3 v.s. T1    0.17 (0.10--0.28)    \< 0.001

  Model 2                   T2 v.s. T1\              0.95 (0.71--1.28)\   0.759\      Model 2   T2 v.s. T1\   0.67 (0.39--1.14)\   0.141\
                            T3 v.s. T1               0.76 (0.56--1.04)    0.082                 T3 v.s. T1    0.51 (0.29--0.90)    0.021

  Model 3                   T2 v.s. T1\              0.93 (0.69--1.25)\   0.639\      Model 3   T2 v.s. T1\   0.55 (0.31--0.96)\   0.035\
                            T3 v.s. T1               0.73 (0.53--1.00)    0.049                 T3 v.s. T1    0.40 (0.22--0.73)    0.003

  Model 4                   T2 v.s. T1\              0.98 (0.72--1.32)\   0.870\      Model 4   T2 v.s. T1\   0.48 (0.27--0.85)\   0.012\
                            T3 v.s. T1               0.75 (0.54--1.02)    0.070                 T3 v.s. T1    0.37 (0.20--0.69)    0.001

  **Female**                **Female**                                                                                             

  Model 1                   T2 v.s. T1\              1.45 (1.20--1.75)\   \< 0.001\   Model 1   T2 v.s. T1\   0.97 (0.69--1.36)\   0.862\
                            T3 v.s. T1               1.68 (1.22--2.31)    0.001                 T3 v.s. T1    1.55 (1.01--2.38)    0.043

  Model 2                   T2 v.s. T1\              1.06 (0.88--1.28)\   0.529\      Model 2   T2 v.s. T1\   0.70 (0.50--0.98)\   0.040\
                            T3 v.s. T1               1.79 (1.30--2.47)    \< 0.001              T3 v.s. T1    1.16 (0.75--1.78)    0.502

  Model 3                   T2 v.s. T1\              1.06 (0.88--1.28)\   0.521\      Model 3   T2 v.s. T1\   0.68 (0.49--0.96)\   0.027\
                            T3 v.s. T1               1.80 (1.30--2.49)    \< 0.001              T3 v.s. T1    1.08 (0.70--1.67)    0.718

  Model 4                   T2 v.s. T1\              1.06 (0.88--1.28)\   0.559\      Model 4   T2 v.s. T1\   0.68 (0.48--0.96)\   0.028\
                            T3 v.s. T1               1.77 (1.28--2.45)    0.001                 T3 v.s. T1    1.09 (0.71--1.69)    0.695
  --------------------------------------------------------------------------------------------------------------------------------------------

^a^Adjusted covariates:

Model 1 = Unadjusted.

Model 2 = Model 1 + age, race and body mass index (BMI).

Model 3 = Model 2 + serum high-density lipoprotein (HDL), serum fasting glucose, serum total cholesterol , serum total bilirubin, serum aspartate aminotransferase (AST).

Model 4 = Model 3 + history of congestive heart failure (CHF), stroke, malignancy and smoking.

Increasing MAMC tertiles were significantly associated with decreasing HRs for all-cause mortality among 60--90 years old individuals with gamma gap ≥ 3.65 g/dl (Table [2](#T2){ref-type="table"}) and those with BMI 19-24.9 kg/m^2^ and gamma gap ≥ 3.65 g/dl (Table [3](#T3){ref-type="table"}). Moreover, in male participants, the MAMC was in significant association with decreasing HRs for all-cause mortality regardless of the gamma gap levels (Table [4](#T4){ref-type="table"}).

No statistically significant correlation was noted between MAMC and cancer mortality in both gamma gap groups stratified by age (Table [5](#T5){ref-type="table"}). Increasing MAMC tertiles were statistically significant associated with lower HRs for cancer mortality in male participants with gamma gap≥ 3.65 g/dl (Table [6](#T6){ref-type="table"}) and in participants with BMI 19-24.9 kg/m^2^ and gamma gap ≥ 3.65 g/dl (Table [7](#T7){ref-type="table"}).

Participants aged 60--90 years with gamma gap ≥ 3.65 g/dl (Table [8](#T8){ref-type="table"}), those with BMI 19-24.9 kg/m^2^ and gamma gap ≥ 3.65 g/dl (Table [9](#T9){ref-type="table"}), and male participants in group with gamma gap ≥ 3.65 g/dl (Table [10](#T10){ref-type="table"}) had significantly positive association between higher MAMC tertiles and lower HRs for CV mortality. Furthermore, individuals aged 20--39 years with gamma gap \< 3.65 g/dl also had the identical association between MAMC and CV mortality.

According to Tables [2](#T2){ref-type="table"}--[10](#T10){ref-type="table"}, in the group with gamma gap \< 3.65 g/dl, the association between the MAMC tertiles and HRs for all-cause mortality, cancer mortality, and CV mortality were lack of statistical significance.

In conclusion, while the MAMC tertiles increased in the elevated gamma gap group (gamma gap ≥ 3.65 g/dl), individuals with elder age (60--90 years), normal range of BMI (19-24.9 kg/m^2^), and male gender tended to have lower HRs for all-cause mortality, cancer mortality, and CV mortality. The results indicated higher MAMC may be a protective factor of all-cause mortality, cancer mortality, and CV mortality.

DISCUSSION {#s3}
==========

We discovered a statistical significant lowering down of HRs of mortality in higher MAMC tertiles among older male participants with normal BMI values and within the group with gamma gap ≥ 3.65 g/dl. This results showed that higher MAMC may possess protective power over all-cause mortality, cancer mortality, and CV mortality in normal weight older male people with gamma gap ≥ 3.65 g/dl.

Previous literature suggested that MAMC could assist biochemical analysis to characterize undernutrition status \[[@R3]\]. MAMC could represent muscle mass due to its strong correlation with the accurate dual-energy X-ray absorptiometry (DEXA) \[[@R4]\]. Higher MAMC was an indicator of larger lean body mass in maintenance hemodialysis (MHD) patients and was also a potential predictor of better quality of life and survival rate \[[@R4]\]. Combined use of both waist circumference (WC) and MAMC provided simple measures of body composition to assess mortality risk in older men \[[@R5]\]. Moreover, Landi *et al.* reasoned that decreased MAMC was associated with mortality in elderly men and women \[[@R6]\].

Gamma gap is also known as paraprotein gap or globulin gap \[[@R7]\]. High gamma gap has important implications of inflammatory states \[[@R8], [@R9], [@R10]\]. Albumin, the most abundant protein in plasma, serves as a circulating depot for endogenous and exogenous compounds \[[@R11]\]; however, viral infection, malignancies and autoimmune diseases lead to excessive production of immunoglobulins, which raise the level of gamma gap independent of albumin \[[@R12]\]. Despite only few surveys applies gamma gap to predict clinical outcomes, the operational definition of an elevated gamma gap is above 4.0 g/dl \[[@R1]\]. Among hospitalized patients, hypoalbuminemia is a common sign in reflection of inflammation \[[@R13]\]. In addition, other cytokines in inflammatory process stimulate acute-phase proteins production and result in elevation of gamma gaps. Hyperglobulinemia accompanied by hypoalbuminemia is a frequent condition in chronic autoimmune disease \[[@R14]\]. Patients suffering from multiple myeloma or other immunoproliferative disease has been known to show gross divergences of serum proteins constitution in comparison with normal people, including hyperproteinemia and associated change in albumin-globulin ratio (AGR) \[[@R15]\]. A large retrospective cohort study conducted in Korea indicates that subjects with low AGR are at risk for increased all-cause mortality, cancer mortality, and cancer incidence \[[@R16]\]. Juraschek *et al.* asserts gamma gap is in strong association with all-cause mortality and specifically, death from pulmonary diseases \[[@R1]\]. After taking physical activity into consideration, Loprinzi *et al.* illustrate that moderate-to-vigorous physical activity (MVPA) reduces death from any cause among people with elevated gamma gaps \[[@R17]\].

Due to the correlation between high gamma gaps and inflammation, Juraschek et al. speculate that elevated gamma gaps have strong association with mortality \[[@R1]\].

Physical activity has salient influences in lowering down all-cause mortality \[[@R18]\]. Routine exercise modulates body composition through controlling weight and attenuating abdominal adiposity \[[@R19], [@R20]\]. It can enhance lipid profiles \[[@R21], [@R22]\], insulin sensitivity \[[@R23], [@R24]\], cardiac function \[[@R25], [@R26]\] and improve autonomic tone \[[@R27]\] and inflammatory states \[[@R28]\]. During an inflammation process, activated cells produce cytokines, including interleukin-6 (IL-6), interleukin-1β(IL-1β), tumor necrosis factor a (TNF-α), interferon-γ (IFN-γ), and transforming growth factor-β (TGF-β). These pro-inflammatory cytokines impede normal physical function by production of oxygen free radicals, apoptosis, and activation of leukocytes \[[@R29], [@R30], [@R31]\]. Appropriate exercise affects beneficially the inflammatory cytokines, and cause reduction of IL-6 \[[@R32]\], TNF-α \[[@R33]\], and IFN-γ \[[@R34]\]. Considering the above mentioned, we assume appropriate exercise possesses moderation effects on inflammation and plays a major role in lowering down mortality risk among population with high gamma gap. This conclusion is in consistent with Loprinzi *et al.*, who suggests physical activity is beneficial in mortality among patients with high levels of gamma gap \[[@R17]\].

However, evaluating exercise requires standardized questionnaires, even trained personnel, and current investigations utilize different methods to acquire data. These high heterogeneity surveys can engender bias in future performing meta-regression analyses. Therefore, we use measurable anthropometric data in this study to reflect physical activity. As physical activity is associated with muscle mass \[[@R35]\], and MAMC can well represent muscle mass \[[@R4]\], we employed the MAMC to predict mortality of people with normal and elevated gamma gap in this survey. Noteworthy, in the group with gamma gap ≥ 3.65 g/dl, the HRs of all-cause mortality, cancer mortality, and CV mortality decreased as MAMC increased among older male participants. Genetic factors, hormones effects, muscle capacity and physical function may explain for the presence of gender differences of the results \[[@R36], [@R37]\]. Generally, men have higher muscle mass and muscle capacity than women due to hormone effects, such as much higher levels of testosterone in men. Males also have greater muscle strength and higher physical performance than females \[[@R36], [@R37]\].

The study does have a number of caveats. First, NHANES III is a study with single measurement of MAMC during the follow-up period, which may engender biased results. The present study is only having exposure data available at one time point, future work should investigate how altered elevated gamma gap and MAMC influences mortality. Second, a myriad of the clinical factors used in the investigation are based on household claimed data that may not be completely accurate. Third, despite adjustments having been made for a large number of potentially confounding factors, unmeasured confounders of the association between MAMC and cause specific mortalities in US individuals cannot be ruled out.

Despite the aforementioned limitations, the present study corroborates previous work demonstrating an positive correlation between all-cause mortality, cancer mortality, CV mortality and those with gamma gap ≥ 3.65 g/dl, also providing evidence supporting the protective effect of higher MAMC on mortality among individuals with an elevated gamma gap. Future work may benefit by examining the extent to which changes in MAMC influence mortality risk among people with an elevated gamma gap. Future work would also benefit by applying our findings to clinical and epidemiological investigations.

MATERIALS AND METHODS {#s4}
=====================

Data source and participants {#s4_1}
----------------------------

Data were retrieved from the NHANES III (1988--1994), a cross-sectional survey designed to evaluate the health and nutritional status of the noninstitutionalized U.S. adults by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) \[[@R38]\]. Approved by Institutional Review Board (IRB), NHANES III comprised household interviews and physical examinations conducted at mobile examination centers. The NHANES III survey was based on a complex, multistage, stratified and clustered design and was executed in accordance with the Declaration of Helsinki. We selected adults between 20 to 90 years of age in the NHANES III to performed the present study, and these participants were involved with a mean follow-up of 14.3 years.

Follow-up data on all-cause mortality, cancer mortality, and cardiovascular mortality {#s4_2}
-------------------------------------------------------------------------------------

NCHS linked NHANES III survey to death certificate records with the National Death Index (NDI), a computerized database of all certified deaths in the U.S. since 1979 \[[@R39]\]. Linkage of the NHANES III participants with the NDI mortality data provided the opportunity to conduct a vast array of outcome surveys designed to investigate the correlation of health factors with mortality. This file linked NHANES III participants with death records from the NDI through 31 December 2006. The cause of death was coded using the International Classification of Disease (ICD)-9 until 1998 and ICD-10 was used from 1999 onward. To adjust for changes between the two coding systems, final cause of deaths occurring prior to 1999 were re-coded into comparable ICD-10-based underlying cause of death groups \[[@R40]\]. For overall mortality, we included deaths from all causes; for cancer-specific mortality, we included deaths from malignant neoplasms (ICD-10 = C00--C97); for CV diseases related mortality, we included diseases of the heart and circulation system (ICD-10 = I00--I178).

Measurement: gamma gap {#s4_3}
----------------------

According to the original protocol, NHANES III collected a comprehensive serum metabolic data form the participants. The analyses were using the Hitachi Model 704 multichannel analyzer. The NHANES personnel evaluated total protein with a colorimetric assay, while albumin was determined via a Bromocresol purple reagent. Gamma gap was calculated with the following formula: serum total protein (g/dl)--serum albumin (g/dl). In clinical practice, the threshold of gamma gap was 3.5 g/dl or 4.0 g/dl \[[@R1]\]. We conducted the ROC curve for gamma gap. The area under the curve (AUC) was an index of the ability of a marker to discriminate between true positives and true negatives. In the present study, an elevated gamma gap was defined using the cut-point of ≥ 3.65 g/dl.

Measurement: anthropometric parameters {#s4_4}
--------------------------------------

The anthropometric parameters were undertaken using a standard protocol and collection instruments as outlined below. Body height and weight were measured, and converted to BMI in units of kg/m^2^. Have the participants standing upright with relaxed shoulder, and marked at the midpoint posteriorly to the upper arm. Then placed a tape measure around the target point and pressed to the skin surface without tight compress. The operator measured the circumference of the upper arm vertically to the long axis of it. The MAC value was measured to the nearest 0.1 cm. To measure the TS, the operator grasped about 2.0 cm of the TS above the marked point and kept the jaws of the skinfold calipers vertically to the shaft of the arm over the marked point. The TS value was recorded to the nearest 0.1 mm. MAMC (cm), an established measure of muscle protein mass, was calculated as: MAC (cm) − 0.3142 x TS thickness (mm).

Definition of the MAMC tertiles group {#s4_5}
-------------------------------------

We categorized both male and female participants into tertiles based on their MAMC level. The participants in the lowest tertile was defined as the reference group. The gender-specific tertiles were as follows: T1 (15.9--27.3), T2 (27.4--29.7), T3 (29.8--40.9) cm in the male group and T1 (13.8--21.9), T2 (22.0--24.2), T3 (24.3--44.1) cm in the female group.

Measurement: risk variables {#s4_6}
---------------------------

Self-report variables were as the below mentioned: age, gender, ethnicity, smoking status, past medical history diagnosed by a doctor (type 2 DM, skin cancer, other cancer, stroke, CHF, and asthma).

Metabolic variables were obtained from blood samples. The hexokinase enzymatic method was adopted to analyze the plasma glucose according to the Cobas Mira Chemistry System (Roche Diagnostic Systems, Indianapolis, IN, USA). The venipuncture time of the participants was after fasted for 6 hours. Serum TC, serum TG, serum HDL and serum LDL were measured by the Hitachi 704 Analyzer (Roche Diagnostics, Indianapolis, IN, USA). Serum CRP level was measured with latex-enhanced nephelometry (Behring Nephelometer II Analyzer System; Behring Diagnostics Inc., Somerville, NJ, USA). The study utilized the Beckman Synchron LX20 instrument to measure other biochemical profiles, such as serum albumin, serum UA, serum total bilirubin, AST, and ALT. Moreover, MAMC, gamma gap, BMI, SBP, and DBP were listed as continuous variables. The database had past the appraisal of the CDC, and all the profiles were obtained under standardized protocols.

Statistical analysis {#s4_7}
--------------------

Predictive Analytics Suite Workstation Statistics (SPSS Inc., Chicago, IL, USA) (name as SPSS hereinafter) is an integrated software program that addresses the entire analytical process, from planning to data collection to analysis, reporting and deployment. NHANES III was a database with complex survey designs; thus, it was inappropriate to calculate statistical analyses with the assumption of a simple random sample providing incorrect variance estimates. ''Complex Sampling'' was used to incorporate sample weights and adjusted for strata of the complex sample design. Continuous data are presented as means ± standard errors (SE) while categorical data as count and percentages (%). To examine the effect of MAMC and gamma gap on mortality outcomes, we would describe the difference in mortality outcomes between MAMC as a main effect. Similarly, any difference in the level of gamma gap would be presented as a main effect. The presence of an interaction effect implies that the effect of MAMC on mortality outcomes varies as a function of the level of gamma gap. As a first step, the analysis of pooled MAMC values versus pooled gamma gap levels was performed. If positive, interaction tests were performed on all-cause mortality, cancer mortality, and CV mortality to check for any interaction between the different predicting components (MAMC, gamma gap). Independent of the interaction test, an assessment of predicting effect was also performed. An interaction could be ruled out if the statistical interaction test was not significant and the assessment revealed no relevant difference. If an interaction was ruled out, the pooled analysis remained the primary analysis. If an interaction could not be ruled out, then we would divide the gamma gap into subgroups. For further analyses, the ROC curves of gamma gap for detecting all-cause mortality, cancer mortality, and CV mortality were produced. The AUCs with their 95% CIs were calculated. To determine the optimal point, the square root of \[(1 -- sensitivity)^2^ + (1 -- specificity)^2^\] was calculated, which was the point on the ROC curve with the shortest distance from the upper left corner. The study would divide the participants into subgroups according to the cut-off values of gamma gap and measure the influences of MAMC stratified by age (20--39, 40--59, and 60--90 years), BMI (19--24.9, 25--29.9, and ≥ 30 kg/m^2^), and gender on all-cause mortality, cancer mortality and CV mortality.

Table [1](#T1){ref-type="table"} illustrated the demographic characteristics, and the continuous variables were analyzed by trend analyses, while the categorical variables were analyzed by Chi-square test. *P* values of less than 0.05 were considered significant.

Multivariable Cox proportional hazard ratio models stratified by age, BMI, and gender were used to explored the HRs between the MAMC tertiles ratios (T2 v.s. T1 and T3 v.s. T1) and all-cause mortality (Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}), cancer mortality (Tables [5](#T5){ref-type="table"}--[7](#T7){ref-type="table"}), and CV mortality (Tables [8](#T8){ref-type="table"}--[10](#T10){ref-type="table"}) in the two gamma gap groups. The multivariable Cox proportional hazard ratio models were classified into 4 models that adjusted for the following variables:Model 1: unadjusted by other variables.Model 2: age, gender, race and BMI.Model 3: age, gender, race, BMI, serum HDL, serum fasting glucose, serum TC, serum total bilirubin and AST.Model 4: age, gender, race, BMI, serum HDL, serum fasting glucose, serum TC, serum total bilirubin, AST, CHF, stroke, malignancy and smoking.
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